AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 271.22B +25.3% |
| Revenue (ttm) | 50.03B +8.6% |
| Net Income | 8.71B +45.3% |
| EPS | 5.57 +45.3% |
| Shares Out | n/a |
| PE Ratio | 31.14 |
| Forward PE | 20.01 |
| Dividend | 2.47 (1.38%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,528 |
| Average Volume | 1,224 |
| Open | 178.35 |
| Previous Close | 179.00 |
| Day's Range | 171.00 - 178.35 |
| 52-Week Range | 113.25 - 180.45 |
| Beta | n/a |
| RSI | 60.75 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment
AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s (NYSE: ABBV) combination treatment for chronic lymphocytic leukemia (CLL). The FDA has approved the combination of Vencle...
AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment
AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment
CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
AstraZeneca’s CALQUENCE (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lympho...
AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment
AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment
FDA Approves AstraZeneca's Calquence Plus Venetoclax For Chronic Lymphocytic Leukemia
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) on Friday said the US Food and Drug Administration (FDA) has approved its Calquence in combination with venetoclax for the treatment of adults with chronic...
AstraZeneca (AZN) Strikes Major Licensing Deal in China
AstraZeneca (AZN) Strikes Major Licensing Deal in China
EMA Validates Enhertu Application for AstraZeneca (AZN)
EMA Validates Enhertu Application for AstraZeneca (AZN)
Daiichi Sankyo: ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca'...
FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)
FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)
FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals
FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals
AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development
AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development
AstraZeneca, Bristol partner with Evinova to use AI in drug development
Top 3 Health Care Stocks That May Collapse This Quarter
As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Apple, Ulta Beauty, AstraZeneca And A Real Estate Stock On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Joshua Brown , co-founder and CEO of Ritholtz Wealth Management, said he remains long on Apple Inc. (NASDAQ: AAPL). Supporting his view, Wedbush analyst Da...
Impax International Sustainable Economy Fund Q4 2025 Contributors And Detractors
Impax International Sustainable Economy Fund portfolio marginally underperformed MSCI EAFE benchmark, driven primarily by stock-specific effects and style tilts. AstraZeneca's stock has an attractive ...
Final Trades: Apple, AstraZeneca, Vici Properties and Ulta Beauty
The Investment Committee give you their top stocks to watch for the second half.
Top global stories this week: AstraZeneca, Unilever, NatWest among major names
Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus
AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results in Asthma Trials
AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results in Asthma Trials
China charges former AstraZeneca executive – what it means for global pharmaceutical firms
AstraZeneca’s former China head has been formally charged with medical insurance fraud, illegal trading and unlawful collection of personal information, more than a year after he first came under inve...
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable fir...
Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca
After months of rumors drove up its share price, the Chinese drug company has unveiled a record licensing deal with AstraZeneca, only to see its stock tumble Key Takeaways: Going into the deal, CSPC's...
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments Propel Future Prospects
Q4 2025 AstraZeneca PLC Earnings Call Transcript
Q4 2025 AstraZeneca PLC Earnings Call Transcript